About
Technology
Issues
FAQ
Links
Official Page
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.